Why Viking Therapeutics, Inc.’s (VKTX) Stock Is Down 7.85%
As of Thursday, November 05, Viking Therapeutics, Inc.’s VKTX share price has dipped by 7.85%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Commentary & Analysis
Why Viking Therapeutics, Inc.’s (VKTX) Stock Is Up 6.54%
As of Thursday, October 29, Viking Therapeutics, Inc.’s VKTX share price has surged by 6.54%, which has investors questioning if this is right time to sell.Michael Rose
Why Viking Therapeutics, Inc.’s (VKTX) Stock Is Up 6.50%
As of Thursday, October 15, Viking Therapeutics, Inc.’s VKTX share price has surged by 6.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Viking Therapeutics, Inc.’s (VKTX) Stock Is Down 12.83%
As of Thursday, September 24, Viking Therapeutics, Inc.’s VKTX share price has dipped by 12.83%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Viking Therapeutics, Inc.’s (VKTX) Stock Is Down 13.18%
As of Thursday, September 24, Viking Therapeutics, Inc.’s VKTX share price has dipped by 13.18%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | VKTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,422.7 | $219.9 | 62% |
|
| Shares Out (Mil) | 118.1 | 54.1 | 65% |
|
| Institutional Ownership | 96.4% | 92.9% | 70% |
|
| Float (Mil) | 124.6 | 41.4 | 65% |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 4,208 | 522 | 89% |
|
| Price Change (52-week) |
(26.4%) | 44.7% | 31% |
|
| Growth | VKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (55.5%) | (10.1%) | 6% |
|
| EPS (5yr) | (42.5%) | 15.8% | 5 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 33.5% | (15.7%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 17 | 18 | |
| Current EPS | ($1.347) | ($5.311) | ($5.126) | |
| Month Ago EPS | ($1.098) | ($4.601) | ($4.399) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($1.107) | ($4.627) | ($4.334) | |
| Year/Year Chg | (13.2%) | 66.4% | 20.0% | |
| Financials | VKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($627) | ($44) | 2% |
|
| EPS (TTM) | ($5.408) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($463) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $577 | $0 | 92% |
|
| Long-Term Debt (Q1) (Mil) | $255 | $4 | 52% |
|
| Enterprise Value (Q1) (Mil) | $2,774 | $166 | 53% |
|
| Valuation | VKTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.81 | 2.06 | 84% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VKTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (73.1%) | (47.5%) | 8% |
|
| ROE | (96.4%) | (52.7%) | 9% |
|
| Liabilities to Assets | 39.8% | 29.6% | 30% |
|
| F-Score | 1 | 3 | 1% |
|
Viking Therapeutics, Inc. did not pass any screens on 11/6/2026.
